Costs and consequences of the US Centers for Disease Control and Prevention's recommendations for opt-out HIV testing

David R Holtgrave, David R Holtgrave

Abstract

Background: The United States Centers for Disease Control and Prevention (CDC) recently recommended opt-out HIV testing (testing without the need for risk assessment and counseling) in all health care encounters in the US for persons 13-64 years old. However, the overall costs and consequences of these recommendations have not been estimated before. In this paper, I estimate the costs and public health impact of opt-out HIV testing relative to testing accompanied by client-centered counseling, and relative to a more targeted counseling and testing strategy.

Methods and findings: Basic methods of scenario and cost-effectiveness analysis were used, from a payer's perspective over a one-year time horizon. I found that for the same programmatic cost of US$864,207,288, targeted counseling and testing services (at a 1% HIV seropositivity rate) would be preferred to opt-out testing: targeted services would newly diagnose more HIV infections (188,170 versus 56,940), prevent more HIV infections (14,553 versus 3,644), and do so at a lower gross cost per infection averted (US$59,383 versus US$237,149). While the study is limited by uncertainty in some input parameter values, the findings were robust across a variety of assumptions about these parameter values (including the estimated HIV seropositivity rate in the targeted counseling and testing scenario).

Conclusions: While opt-out testing may be able to newly diagnose over 56,000 persons living with HIV in one year, abandoning client-centered counseling has real public health consequences in terms of HIV infections that could have been averted. Further, my analyses indicate that even when HIV seropositivity rates are as low as 0.3%, targeted counseling and testing performs better than opt-out testing on several key outcome variables. These analytic findings should be kept in mind as HIV counseling and testing policies are debated in the US.

Conflict of interest statement

Competing Interests: The author has declared that no competing interests exist.

References

    1. Centers for Disease Control and Prevention. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55:1–18.
    1. American Medical Association. AMA welcomes new Centers for Disease Control and Prevention (CDC) recommendations for routine HIV testing. 2006. Available: . Accessed 4 May 2007.
    1. American Civil Liberties Union. ACLU says new CDC HIV testing recommendations raise health and civil liberties concerns. 2006. Available: . Accessed 4 May 2007.
    1. National Association of People with AIDS. National Association of People with AIDS supports routinely offered and voluntary HIV Counseling, testing, and referral services. 2006. Available: . Accessed 4 May 2007.
    1. Kamb ML, Fishbein M, Douglas JM, Rhodes F, Rogers J, et al. Efficacy of risk reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases. JAMA. 1998;280:1161–1167.
    1. Kamb ML, Peterman TA, Wolitski RJ. Prevention counseling for HIV-negative persons. Am J Public Health. 2000;90:1152.
    1. Centers for Disease Control and Prevention. Most definitive study to date on effectiveness of HIV counseling and testing finds significant reduction in sexually transmitted diseases. 1998. Available: . Accessed 4 May 2007.
    1. Chou R, Hoyt Huffman L, Fu R, Smits AK, Korthuis PT. Screening for HIV: A review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2005;143:55–73.
    1. Centers for Disease Control and Prevention. HIV testing in healthcare settings. 2006. Available: . Accessed 4 May 2007.
    1. Kaiser Family Foundation. Forum on CDC's new HIV testing recommendations. 2006. Available: . Accessed 4 May 2007.
    1. US Office of Management and Budget. Memorandum for heads of executive departments and establishments: Guidelines and discount rates for benefit-cost analysis of federal programs. 1992. Available: . Accessed 4 May 2007.
    1. Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med. 2005;352:570–585.
    1. Paltiel AD, Weinstein MC, Kimmel AD, Seage GR, 3rd, Losina E, et al. Expanded screening for HIV in the United States—An analysis of cost-effectiveness. N Engl J Med. 2005;352:586–595.
    1. Bozzette SA. Routine screening for HIV infection—Timely and cost-effective. N Engl J Med. 2005;352:620–621.
    1. Centers for Disease Control and Prevention. A glance at the HIV/AIDS epidemic. 2006. Available: . Accessed 4 May 2007.
    1. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
    1. Holtgrave DR, editor. Handbook of economic evaluation of HIV prevention programs. New York: Plenum Press; 1998.
    1. Central Intelligence Agency. The world factbook: United States. 2006. Available: . Accessed 4 May 2007.
    1. US Census Bureau. U.S. POPClock projection. 2006. Available: . Accessed 4 May 2007.
    1. University of Kansas Population Research Institute. United States 2000 population by age by gender. 2006. Available: . Accessed 4 May 2007.
    1. Centers for Disease Control and Prevention. Missed opportunities for earlier diagnosis of HIV infection—South Carolina, 1997–2005. MMWR Morb Mortal Wkly Rep. 2006;55:1269–1272.
    1. McGlynn EA, Asch SM, Adams J, Keesey J, Hicks J, et al. The quality of health care delivered to adults in the United States. N Engl J Med. 2003;348:2635–2645.
    1. Kaiser Family Foundation. HIV testing in the United States. 2006. Available: . Accessed 4 May 2007.
    1. Holtgrave DR. The President's Fiscal Year 2007 Initiative for Human Immunodeficiency Virus Counseling and Testing Expansion in the United States: A scenario analysis of its coverage, impact, and cost-effectiveness. J Public Health Manag Pract. 2007;13:239–243.
    1. Ekwueme DU, Pinkerton SD, Holtgrave DR, Branson BM. Cost-comparison of three HIV counseling and testing technologies. Am J Prev Med. 2003;25:112–121.
    1. Varghese B, Peterman TA, Holtgrave DR. Cost-effectiveness of counseling and testing and partner notification: A decision analysis. AIDS. 1999;13:1745–1751.
    1. Holtgrave DR, DiFranceisco W, Reiser W, Resenhoeft R, Hoxie N, et al. Setting standards for the Wisconsin HIV counseling and testing program: An application of threshold analysis. J Public Health Manag Pract. 1997;3:42–49.
    1. DiFranceisco WJ, Holtgrave DR, Hoxie N, Reiser W, Resenhoeft R, et al. HIV seropositivity rates in outreach-based counseling and testing services: A program evaluation. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;19:282–288.
    1. Wood RJ, Dunphy C, Okita K, Swenson P. Two “HIV-infected” persons not really infected. Arch Intern Med. 2003;163:1857–1859.
    1. Chen RY, Accortt NA, Westfall AO, Mugavero MJ, Raper RJ, et al. Distribution of health care expenditures for HIV-infected patients. Clin Infect Dis. 2006;42:1003–1010.
    1. Marks G, Crepaz N, Janssen RS. Estimating the sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS. 2006;20:1447–1450.
    1. Holtgrave DR. Estimation of annual HIV transmission rates in the United States, 1978–2000. J Acquir Immune Defic Syndr. 2004;35:89–92.
    1. Holtgrave DR, Anderson T. Utilizing HIV transmission rates to assist in prioritizing HIV prevention services. Int J STD AIDS. 2004;15:789–792.
    1. Holtgrave DR, Pinkerton SD. Can increasing awareness of HIV seropositivity decrease infections by 50% in the United States? J Acquir Immune Defic Syndr. 2007;44:360–363.
    1. Anderson JE, Chandra A, Mosher WD. HIV testing in the United States, 2002. Advance data from vital and health statistics. 2005. Available: . Accessed 4 May 2007.
    1. Anderson JE, Mosher WD, Chandra A. Measuring HIV risk in the U.S. population aged 15–44: Results from cycle 6 of the National Survey of Family Growth. Advance data from vital and health statistics. 2006. Available: . Accessed 4 May 2007.
    1. Holtgrave DR, McGuire J, Milan J., Jr The magnitude of key HIV prevention challenges in the United States: Implications for the new national HIV prevention plan. Am J Public Health. 2007. In press.
    1. Committee on the Public Financing and Delivery of HIV Care, Institute of Medicine. Public financing and delivery of HIV/AIDS care: Securing the legacy of Ryan White. Washington (D. C.): National Academy Press; 2005.
    1. Phillips KA, Fernyak S. The cost-effectiveness of expanded HIV counseling and testing in primary care settings: A first look. AIDS. 2000;14:2159–2169.
    1. Fernyak SE, Page-Shafer K, Kellogg TA, McFarland W, Katz MH. Risk behaviors and HIV incidence among repeat tests at publicly funded HIV testing sites in San Francisco. J Acquir Immune Defic Syndr. 2002;31:63–70.
    1. MacKellar DA, Valleroy LA, Secura GM, Barthelow BN, McFarland W, et al. Repeat HIV testing, risk behaviors, and HIV seroconversion among young men who have sex with men: A call to monitor and improve the practice of prevention. J Acquir Immune Defic Syndr. 2002;29:76–85.
    1. Centers for Disease Control and Prevention. HIV-related knowledge and stigma—United States, 2000. MMWR Morb Mortal Wkly Rep. 2000;49:1062–1064.
    1. Kaiser Family Foundation. Summary and chartpack: 2006 Kaiser Family Foundation survey of Americans on HIV/AIDS. 2006. Available: . Accessed 4 May 2007.
    1. Holtgrave DR, Kates J. An exploratory correlational analysis of HIV incidence and CDC's HIV prevention budget. Am J Prev Med. 2007;32:63–67.
    1. Holtgrave DR, Pinkerton SD. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:54–62.
    1. Schackman BR, Gebo KA, Walensky RP, Losina E, Muccio T, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Medical Care. 2006;44:990–997.
    1. Paltiel AD, Walensky RP, Schackman BR, Seage GR, 3rd, Mercincavage LM, et al. Expanded HIV screening in the United States: Effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med. 2006;145:797–806.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir